PL2203462T3 - Proleki fosforamidanu nukleozydu - Google Patents

Proleki fosforamidanu nukleozydu

Info

Publication number
PL2203462T3
PL2203462T3 PL08732818T PL08732818T PL2203462T3 PL 2203462 T3 PL2203462 T3 PL 2203462T3 PL 08732818 T PL08732818 T PL 08732818T PL 08732818 T PL08732818 T PL 08732818T PL 2203462 T3 PL2203462 T3 PL 2203462T3
Authority
PL
Poland
Prior art keywords
phosphoramidate prodrugs
nucleoside phosphoramidate
nucleoside
prodrugs
phosphoramidate
Prior art date
Application number
PL08732818T
Other languages
English (en)
Inventor
Michael Joseph Sofia
Jinfa Du
Peiyuan Wang
Dhanapalan Nagarathnam
Original Assignee
Gilead Pharmasset Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39808855&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2203462(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Pharmasset Llc filed Critical Gilead Pharmasset Llc
Publication of PL2203462T3 publication Critical patent/PL2203462T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
PL08732818T 2007-03-30 2008-03-26 Proleki fosforamidanu nukleozydu PL2203462T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US90931507P 2007-03-30 2007-03-30
US98230907P 2007-10-24 2007-10-24
US12/053,015 US7964580B2 (en) 2007-03-30 2008-03-21 Nucleoside phosphoramidate prodrugs
PCT/US2008/058183 WO2008121634A2 (en) 2007-03-30 2008-03-26 Nucleoside phosphoramidate prodrugs
EP08732818.3A EP2203462B1 (en) 2007-03-30 2008-03-26 Nucleoside phosphoramidate prodrugs

Publications (1)

Publication Number Publication Date
PL2203462T3 true PL2203462T3 (pl) 2015-01-30

Family

ID=39808855

Family Applications (3)

Application Number Title Priority Date Filing Date
PL14179358T PL2826784T3 (pl) 2007-03-30 2008-03-26 Proleki amidofosforanów nukleozydów
PL14169060.2T PL2801580T3 (pl) 2007-03-30 2008-03-26 Proleki amidofosforanów nukleozydów
PL08732818T PL2203462T3 (pl) 2007-03-30 2008-03-26 Proleki fosforamidanu nukleozydu

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL14179358T PL2826784T3 (pl) 2007-03-30 2008-03-26 Proleki amidofosforanów nukleozydów
PL14169060.2T PL2801580T3 (pl) 2007-03-30 2008-03-26 Proleki amidofosforanów nukleozydów

Country Status (36)

Country Link
US (10) US7964580B2 (pl)
EP (7) EP2792680A1 (pl)
JP (8) JP5318085B2 (pl)
KR (3) KR101527701B1 (pl)
CN (8) CN109776637B (pl)
AR (1) AR066898A1 (pl)
AU (1) AU2008232827C1 (pl)
BR (2) BRPI0809654A2 (pl)
CA (1) CA2682230C (pl)
CL (1) CL2008000902A1 (pl)
CO (1) CO6260023A2 (pl)
CY (2) CY1115488T1 (pl)
DE (1) DE202008018643U1 (pl)
DK (1) DK2203462T3 (pl)
ES (3) ES2963716T3 (pl)
FR (1) FR14C0082I2 (pl)
HK (2) HK1206033A1 (pl)
HR (1) HRP20140667T1 (pl)
HU (1) HUS1400059I1 (pl)
IL (3) IL201239A (pl)
LT (1) LTC2203462I2 (pl)
LU (1) LU92600I2 (pl)
MX (1) MX2009010401A (pl)
MY (1) MY147409A (pl)
NL (1) NL300704I1 (pl)
NO (1) NO2014029I1 (pl)
NZ (2) NZ599206A (pl)
PH (1) PH12014502771A1 (pl)
PL (3) PL2826784T3 (pl)
PT (3) PT2801580T (pl)
RU (4) RU2651892C3 (pl)
SG (2) SG179445A1 (pl)
SI (3) SI2203462T1 (pl)
TW (1) TWI357332B (pl)
WO (1) WO2008121634A2 (pl)
ZA (2) ZA200906647B (pl)

Families Citing this family (249)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
AU2001272923A1 (en) 2000-05-26 2001-12-11 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
CA2434386C (en) 2001-01-22 2006-12-05 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
JP2006519753A (ja) 2002-11-15 2006-08-31 イデニクス（ケイマン）リミテツド ２’−分枝ヌクレオシドおよびフラビウイルス科ウイルス突然変異
SI2604620T1 (sl) 2003-05-30 2016-10-28 Gilead Pharmasset LLC c/o Gilead Sciences, Inc. Modificirani fluorirani nukleozidni analogi
EP1827460A4 (en) 2004-12-09 2012-03-14 Univ Minnesota NUCLEOSIDE WITH ANTIVIRAL AND ANTI-CANCER EFFECT
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
KR101645742B1 (ko) 2008-04-23 2016-08-04 길리애드 사이언시즈, 인코포레이티드 항바이러스 치료를 위한 카바-뉴클레오사이드 유사체
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010068708A2 (en) 2008-12-09 2010-06-17 Rfs Pharma, Llc 3'-azido purine nucleotide prodrugs for treatment of viral infections
EA019295B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Соединения пуриновых нуклеозидов и способ их получения
WO2010075517A2 (en) * 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside analogs
MX2011006891A (es) 2008-12-23 2011-10-06 Pharmasset Inc Fosforamidatos de nucleosidos.
EP2393815A4 (en) * 2009-02-06 2012-11-21 Rfs Pharma Llc PURIN NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR THE TREATMENT OF CANCER AND VIRUS INFECTIONS
KR20110128947A (ko) * 2009-03-20 2011-11-30 앨리오스 바이오파마 인크. 치환된 뉴클레오시드 및 뉴클레오티드 유사체
JP5582662B2 (ja) 2009-05-13 2014-09-03 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス化合物
AU2016200676B2 (en) * 2009-05-20 2017-06-01 Gilead Pharmasset Llc N-[(2'R)-2 '-deoxy-2'-fluoro-2'-methyl-p-phenyl-5'-uridylyl] -L-alanine 1-methylethyl ester and process for its production
TWI583692B (zh) * 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
AU2014274548B2 (en) * 2009-05-20 2016-02-04 Gilead Pharmasset Llc N- [ (2 ' R) -2 ' -deoxy-2 ' -fluoro-2 ' -methyl-p-phenyl-5 ' -uridylyl] -L-alanine 1-methylethyl ester and process for its production
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
US9676797B2 (en) 2015-09-02 2017-06-13 Abbvie Inc. Anti-viral compounds
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
SI2480559T1 (sl) 2009-09-21 2013-10-30 Gilead Sciences, Inc. Postopki in intermediati za pripravo 1'-ciano-karbanukleozidnih analogov
US8552021B2 (en) * 2009-09-29 2013-10-08 Janssen Products, L.P. Phosphoramidate derivatives of nucleosides
CN102596201A (zh) 2009-10-30 2012-07-18 贝林格尔.英格海姆国际有限公司 包含BI201335、干扰素α和利巴韦林的HCV组合治疗的用药方案
EA201200890A1 (ru) * 2009-12-18 2013-01-30 Бёрингер Ингельхайм Интернациональ Гмбх Комбинированная терапия hcv
HUE034239T2 (en) * 2010-03-31 2018-02-28 Gilead Pharmasset Llc Method for Crystallization of (S) -isopropyl 2 - (((S) (perfluorophenoxy) (phenoxy) phosphoryl) amino) propanoate \ t
EP3290428B1 (en) 2010-03-31 2021-10-13 Gilead Pharmasset LLC Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
US9023788B2 (en) 2010-04-20 2015-05-05 New York University Methods compounds and pharmaceutical compositions for treating anxiety and mood disorders
ES2524398T3 (es) * 2010-07-19 2014-12-09 Gilead Sciences, Inc. Métodos para la preparación de profármacos de fosforoamidato diastereoméricamente puros
WO2012012776A1 (en) 2010-07-22 2012-01-26 Gilead Sciences, Inc. Methods and compounds for treating paramyxoviridae virus infections
EP2619215B1 (en) 2010-09-22 2018-09-05 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
NZ607996A (en) 2010-09-22 2014-07-25 Alios Biopharma Inc Substituted nucleotide analogs
EP2646453A1 (en) 2010-11-30 2013-10-09 Gilead Pharmasset LLC Compounds
WO2012094248A1 (en) * 2011-01-03 2012-07-12 Nanjing Molecular Research, Inc. O-(substituted benzyl) phosphoramidate compounds and therapeutic use
WO2012117246A1 (en) 2011-03-01 2012-09-07 Nucana Biomed Limited Phosphoramidate derivatives of 5 - fluoro - 2 ' - deoxyuridine for use in the treatment of cancer
WO2012125900A1 (en) 2011-03-16 2012-09-20 Enanta Pharmaceuticals, Inc. 2'-allene-substituted nucleoside derivatives
CA2843324A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2012142523A2 (en) * 2011-04-13 2012-10-18 Gilead Sciences, Inc. 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment
BR112013029761A2 (pt) * 2011-05-19 2017-03-21 Univ Emory pró-drogas de monofosfato de purina para tratamento de infecções virais
US20130018011A1 (en) * 2011-06-10 2013-01-17 Hassan Javanbakht Method of treating dengue fever
WO2013013009A2 (en) * 2011-07-19 2013-01-24 Nanjing Molecular Research, Inc. 2',3'-DIDEOXY-2'-α-FLUORO-2'-β-C-METHYLNUCLEOSIDES AND PRODRUGS THEREOF
TW201329096A (zh) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
DE202012013074U1 (de) 2011-09-16 2014-10-29 Gilead Pharmasset Lcc Zusammensetzungen zur Behandlung von HCV
JP6162125B2 (ja) 2011-09-30 2017-07-12 タフツ・ユニバーシティ 神経変性障害を処置するためのウリジン二リン酸誘導体、組成物および方法
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
JP5677645B2 (ja) 2011-10-21 2015-02-25 アッヴィ・インコーポレイテッド 少なくとも２種の直接作用型抗ウイルス剤、およびリバビリンを含むがインターフェロンを含まない、ｈｃｖを治療するための方法
CN104436197A (zh) * 2011-10-21 2015-03-25 艾伯维公司 至少两种直接作用抗病毒剂的组合产品
BR112014010295A2 (pt) 2011-10-31 2017-04-18 Gilead Pharmassett Llc métodos e composições para o tratamento de vírus de hepatite c
BR112014012739A8 (pt) 2011-11-29 2017-06-20 Gilead Pharmasset Llc composições e métodos para o tratamento do vírus da hepatite c
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CN104185420B (zh) 2011-11-30 2017-06-09 埃默里大学 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
US9708357B2 (en) * 2011-12-20 2017-07-18 Riboscience, LLC 4′-azido, 3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication
EA024297B1 (ru) * 2011-12-20 2016-09-30 Рибосайенс Ллк 2',4'-дифтор-2'-метилзамещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с
EP2794630A4 (en) 2011-12-22 2015-04-01 Alios Biopharma Inc SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE
BR112014014740B1 (pt) 2011-12-22 2021-08-24 Alios Biopharma, Inc Compostos de nucleosídeos, nucleotídeos e análogos destes, seu uso e composição farmacêutica
JP5781706B2 (ja) * 2011-12-29 2015-09-24 アッヴィ・アイルランド・アンリミテッド・カンパニー Ｈｃｖ阻害剤を含む固体組成物
US9303652B2 (en) 2012-01-05 2016-04-05 Archipelago Group Llc Electric blower operable to provide combustion air to a fire
RU2014136887A (ru) 2012-02-14 2016-04-10 Юниверсити Оф Джорджиа Рисерч Фаундэйшн, Инк. Спиро[2.4]гептаны для лечения инфекций, вызванных flaviviridae
WO2013142124A1 (en) 2012-03-21 2013-09-26 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
WO2013173759A2 (en) * 2012-05-17 2013-11-21 Enanta Pharmaceuticals, Inc. Macrocyclic nucleoside phosphoramidate derivatives
JP6165848B2 (ja) * 2012-05-22 2017-07-19 イデニク ファーマシューティカルズ エルエルシー 肝疾患のためのｄ−アミノ酸化合物
EP2852605B1 (en) 2012-05-22 2018-01-31 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphate prodrugs for hcv infection
US9109001B2 (en) 2012-05-22 2015-08-18 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphoramidate prodrugs for HCV infection
SG11201407336PA (en) 2012-05-25 2015-03-30 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
US9206412B2 (en) * 2012-05-31 2015-12-08 Colorado State University Research Foundation Thioxothiazolidine inhibitors
CN104640444B (zh) * 2012-06-16 2016-12-14 河南美泰宝生物制药有限公司 双肝脏靶向氨基磷酸酯和氨基膦酸酯前药
WO2014008236A1 (en) 2012-07-03 2014-01-09 Bristol-Myers Squibb Company Process for preparing diastereomerically enriched phosphoramidate derivatives of nucleoside compounds for treatment of viral infections
WO2014047117A1 (en) 2012-09-18 2014-03-27 Bristol-Myers Squibb Company Process for preparing phosphoramidate derivatives of nucleoside compounds for treatment of viral infections
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
US9163055B2 (en) 2012-09-28 2015-10-20 Tufts University Methods for treating glaucoma using uridine diphosphate derivatives
AP2015008384A0 (en) * 2012-10-08 2015-04-30 Univ Montpellier Ct Nat De La Rech Scient 2'-Chloro nucleoside analogs for hcv infection
EP2909222B1 (en) 2012-10-22 2021-05-26 Idenix Pharmaceuticals LLC 2',4'-bridged nucleosides for hcv infection
US20140140952A1 (en) * 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Sp-Nucleoside Analog
WO2014078427A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of rp-nucleoside analog
SG11201503750YA (en) * 2012-11-16 2015-06-29 Univ Cardiff Process for preparing nucleoside prodrugs
WO2014099941A1 (en) * 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
CA2894542C (en) 2012-12-21 2023-10-31 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
SG10201706949VA (en) 2013-01-31 2017-09-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US10034893B2 (en) * 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
US20140249101A1 (en) 2013-03-04 2014-09-04 Gilead Pharmasset Llc Methods for treating hepatitis c virus infection
KR101857337B1 (ko) * 2013-03-08 2018-05-11 난징 산홈 팔마세우티칼 컴퍼니 리미티드 신규한 뉴클레오시드 포스포라미데이트 화합물 및 이의 용도
CA2904180C (en) 2013-03-13 2022-05-10 Tufts University Uridine nucleoside derivatives, compositions and methods of use
US20140271547A1 (en) 2013-03-13 2014-09-18 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
US10138265B2 (en) 2013-03-13 2018-11-27 Tufts University Uridine nucleoside derivatives, compositions and methods of use
RU2534613C2 (ru) * 2013-03-22 2014-11-27 Александр Васильевич Иващенко Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения
EP2981542B1 (en) * 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
WO2014169280A2 (en) 2013-04-12 2014-10-16 Achillion Pharmaceuticals, Inc. Deuterated nucleoside prodrugs useful for treating hcv
PE20160120A1 (es) * 2013-05-16 2016-02-24 Riboscience Llc Derivados de nucleosido 4'-fluoro-2'-metilo sustituido
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
US20140357595A1 (en) 2013-06-04 2014-12-04 Gilead Pharmasset Llc Methods of preventing and treating recurrence of a hepatitis c virus infection in a subject after the subject has received a liver transplant
EP3004130B1 (en) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucleosides for the treatment of hcv
WO2014194826A1 (zh) * 2013-06-06 2014-12-11 南京圣和药业有限公司 三环稠杂环类核苷氨基磷酸酯化合物、其制备方法及应用
NZ714415A (en) 2013-06-26 2017-09-29 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US20150037282A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
EP4005560A1 (en) 2013-08-27 2022-06-01 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
UA117375C2 (uk) * 2013-09-04 2018-07-25 Медівір Аб Інгібітори полімерази hcv
WO2015038596A1 (en) 2013-09-11 2015-03-19 Emory University Nucleotide and nucleoside compositions and uses related thereto
WO2015042447A1 (en) 2013-09-20 2015-03-26 Isis Pharmaceuticals, Inc. Targeted therapeutic nucleosides and their use
CN104447923B (zh) * 2013-09-23 2018-03-30 中国药科大学 2’‑脱氧‑2’‑氟‑2’‑甲基核苷衍生物及其制备方法与在制药中的用途
US8889701B1 (en) 2013-10-11 2014-11-18 Alla Chem, Llc Substituted (S)-(2R,3R,5R)-3-hydroxy-(5-pyrimidin-1-yl)tetrahydrofuran-2-ylmethyl aryl phosphoramidate
TW201524990A (zh) 2013-10-11 2015-07-01 Alios Biopharma Inc 經取代之核苷、核苷酸及其類似物
US20160271160A1 (en) 2013-10-17 2016-09-22 Medivir Ab Hcv polymerase inhibitors
WO2015061683A1 (en) * 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
CN104650171A (zh) * 2013-11-25 2015-05-27 天津市汉康医药生物技术有限公司 索氟布韦倍半水合物化合物
US20170198005A1 (en) * 2013-11-27 2017-07-13 Idenix Pharmaceuticals Llc 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
RU2553996C1 (ru) * 2013-11-27 2015-06-20 Андрей Александрович Иващенко Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты
US20150150897A1 (en) 2013-12-02 2015-06-04 Gilead Pharmasset Llc Methods of treating hepatitis c virus infection in subjects with cirrhosis
CA2934786A1 (en) 2013-12-23 2015-07-02 Mylan Laboratories Ltd. Process for the preparation of sofosbuvir
TW201609785A (zh) * 2013-12-23 2016-03-16 吉李德製藥公司 固體型之抗病毒化合物
CN104761604A (zh) * 2014-01-02 2015-07-08 江苏豪森药业股份有限公司 尿嘧啶核苷酸类似物及其制备方法和应用
WO2015126995A1 (en) 2014-02-20 2015-08-27 Ratiopharm Gmbh Solid state forms of sofosbuvir
CN103804446A (zh) * 2014-02-27 2014-05-21 苏州东南药业股份有限公司 一种3,5-二苯甲酰基-2-去氧-2-氟-2甲基-D-核糖-γ-内酯的制备方法
EP3114122A1 (en) 2014-03-05 2017-01-11 Idenix Pharmaceuticals LLC Solid forms of a flaviviridae virus inhibitor compound and salts thereof
WO2015134780A1 (en) * 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv
WO2015134561A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
CZ307789B6 (cs) 2014-04-15 2019-05-09 Zentiva, K.S. Způsob výroby biologicky účinných fosforamidátových léčiv
EP3131914B1 (en) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
WO2015164812A1 (en) * 2014-04-24 2015-10-29 Cocrystal Pharma, Inc. 2' -disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
EP3154526B1 (en) 2014-06-13 2019-03-06 ratiopharm GmbH Solid state forms of sofosbuvir
EA201692507A1 (ru) 2014-06-23 2017-04-28 Сановель Илач Санайи Ве Тиджарет А.Ш. Фармацевтические комбинации софосбувира и рибавирина
EA201692514A1 (ru) 2014-06-23 2017-04-28 Сановель Илач Санайи Ве Тиджарет А.Ш. Фармацевтические композиции на основе софосбувира и рибавирина с модифицированным высвобождением
EP2959888A1 (en) 2014-06-23 2015-12-30 Sanovel Ilac Sanayi ve Ticaret A.S. A novel pharmaceutical composition of sofosbuvir and ribavirin
CZ2014502A3 (cs) 2014-07-17 2016-01-27 Zentiva, K.S. Nová forma sofosbuviru a způsob její přípravy
CN105315319B (zh) * 2014-07-30 2020-11-20 南京圣和药业股份有限公司 丙型肝炎病毒抑制剂及其应用
WO2016016865A1 (en) 2014-08-01 2016-02-04 Lupin Limited A process for the preparation of nucleoside phosphoramidate
WO2016023522A2 (en) * 2014-08-15 2016-02-18 Merck Sharp & Dohme Corp. Substituted phosphoramidate compounds and uses thereof
WO2016033164A1 (en) 2014-08-26 2016-03-03 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
WO2016035006A1 (en) * 2014-09-01 2016-03-10 Dr. Reddy’S Laboratories Limited Novel nucleotide analogs, process for the preparation of sofosbuvir and its analogs, novel forms of sofosbuvir and solid dispersion of sofosbuvir
WO2016038542A2 (en) 2014-09-10 2016-03-17 Mylan Laboratories Limited Polymorphic forms of sofosbuvir
WO2016042576A1 (en) 2014-09-16 2016-03-24 Cadila Healthcare Limited Co-crystal of sofosbuvir and amino acid and process for preparation thereof
WO2016064797A1 (en) * 2014-10-20 2016-04-28 Merck Sharp & Dohme Corp. Process for making nucleoside phosphoramidate compounds
TWI767201B (zh) 2014-10-29 2022-06-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
EP3212658A4 (en) * 2014-10-31 2018-07-25 Cocrystal Pharma, Inc. 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
US9718851B2 (en) 2014-11-06 2017-08-01 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
WO2016074596A1 (zh) * 2014-11-10 2016-05-19 南京曼杰生物科技有限公司 核苷氨基磷酸酯衍生物及其应用
RU2567854C1 (ru) * 2014-11-11 2015-11-10 Александр Васильевич Иващенко Нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения
CN105294795B (zh) * 2014-11-20 2019-01-15 南京曼杰生物科技有限公司 核苷氨基磷酸酯衍生物及其应用
US9732110B2 (en) 2014-12-05 2017-08-15 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
JP6735751B2 (ja) * 2014-12-15 2020-08-05 エモリー ユニバーシティー Ｂ型肝炎ウイルスの治療のためのホスホルアミデート
CA2975813A1 (en) 2015-02-13 2016-08-18 Sandoz Ag Pharmaceutical compositions comprising ledipasvir and sofosbuvir
ITUB20150109A1 (it) * 2015-03-05 2016-09-05 Hc Pharma Ag Composti utili per il trattamento dell'epatite c
AU2016229966B2 (en) * 2015-03-06 2018-09-27 Atea Pharmaceuticals, Inc. Beta-D-2'-deoxy-2'alpha-fluoro-2'-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
US10407456B2 (en) 2015-03-26 2019-09-10 Quimica Sintetica, S.A. Nucleoside phosphoramidates useful for the treatment of viral infections and preparation thereof
CN106146588A (zh) * 2015-03-26 2016-11-23 常州制药厂有限公司 一种索非布韦的制备方法
ITUB20152109A1 (it) * 2015-07-13 2017-01-13 Quim Sintetica S A Nucleosidi fosforamidati utili per il trattamento di infezioni virali e loro preparazione
CN106188192B (zh) * 2015-04-29 2019-09-10 刘沛 含d-氨基酸酯的核苷氨基磷酸/膦酸酯衍生物及其医药用途
CN106188193A (zh) * 2015-05-07 2016-12-07 苏州旺山旺水生物医药有限公司 (2`r)-2`-脱氧-2`-卤代-2`-甲基脲苷衍生物、其制备方法和用途
CN104829672B (zh) * 2015-05-19 2018-03-13 江苏福瑞生物医药有限公司 一种药物中间体的合成方法
WO2016189443A2 (en) * 2015-05-23 2016-12-01 Virupaksha Organics Limited Solid forms of nucleoside phosphoramidate
CN107646037A (zh) 2015-05-26 2018-01-30 桑多斯股份公司 选择性合成核苷氨基磷酸酯类化合物的方法
ES2933032T3 (es) 2015-06-03 2023-01-31 Teva Pharmaceuticals Int Gmbh Procesos mejorados para la preparación de sofosbuvir e intermedios del mismo
CZ2015443A3 (cs) 2015-06-26 2017-01-04 Zentiva, K.S. Farmaceutická formulace sofosbuviru
CN108026136A (zh) 2015-08-06 2018-05-11 奇默里克斯公司 作为有用的抗病毒剂的吡咯并嘧啶核苷及其类似物
EP3133062A1 (en) 2015-08-19 2017-02-22 Zaklady Farmaceutyczne Polpharma SA Process for the preparation of a pharmaceutical agent
WO2017029408A1 (en) 2015-08-20 2017-02-23 Ratiopharm Gmbh Solid state forms of sofosbuvir
CN105061535A (zh) * 2015-09-02 2015-11-18 江苏科本医药化学有限公司 一种索非布韦中间体的合成方法
CN114366745A (zh) 2015-09-16 2022-04-19 吉利德科学公司 治疗沙粒病毒科和冠状病毒科病毒感染的方法
WO2017077552A1 (en) 2015-11-03 2017-05-11 Mylan Laboratories Limited Process for the preparation of sofosbuvir
CN106674318B (zh) * 2015-11-06 2020-04-21 博瑞生物医药（苏州）股份有限公司 一种ns5b聚合酶抑制剂
CN106674319B (zh) * 2015-11-06 2020-04-21 博瑞生物医药（苏州）股份有限公司 一种治疗丙肝的化合物
CN106674320B (zh) * 2015-11-06 2020-04-21 博瑞生物医药（苏州）股份有限公司 一种hcv的治疗药物
JP7019585B2 (ja) * 2015-11-16 2022-02-15 アヴァロ セラピューティクス，インコーポレーテッド 核酸プロドラッグ
WO2017093973A1 (en) * 2015-12-02 2017-06-08 Sun Pharmaceutical Industries Limited Process for the preparation of pure sofosbuvir
ITUB20161079A1 (it) 2016-02-25 2017-08-25 Hc Pharma Ag Procedimento per la preparazione di sofosbuvir
US10738071B2 (en) 2016-03-17 2020-08-11 Mylan Laboratories Limited Polymorphic forms of sofosbuvir
CA3010462A1 (en) * 2016-03-25 2017-09-28 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Uridine phosphoramide prodrug, preparation method therefor, and medicinal uses thereof
WO2017184670A2 (en) 2016-04-22 2017-10-26 Gilead Sciences, Inc. Methods for treating zika virus infections
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF
EP3452447A4 (en) 2016-05-03 2019-12-18 The Regents of The University of California IRES-MEDIATED PROTEIN SYNTHESIS INHIBITORS
CZ2016257A3 (cs) 2016-05-05 2017-11-15 Zentiva, K.S. Amorfní forma sofosbuviru, způsob její přípravy a její stabilizace
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
EP3454862A4 (en) 2016-05-10 2020-02-12 C4 Therapeutics, Inc. SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CA3025633C (en) 2016-05-27 2021-02-23 Gilead Sciences, Inc. Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors
BR102017011025A2 (pt) 2016-06-02 2017-12-19 Gilead Pharmasset Llc Formulation of combination of three antiviral compounds
CN107501247A (zh) * 2016-06-14 2017-12-22 安徽贝克联合制药有限公司 一种尿嘧啶核苷类衍生物的制备方法
US20190192548A1 (en) * 2016-06-20 2019-06-27 Merck Sharp & Dohme Corp. Use of cyclic phosphate substituted nucleoside derivativesfor the treatment of viral diseases
JP2019525905A (ja) 2016-06-24 2019-09-12 エモリー ユニバーシティー Ｂ型肝炎ウイルスの治療のためのホスホロアミデート
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
US10239910B2 (en) * 2016-07-20 2019-03-26 Optimus Drugs (P) Limited Process for the preparation of sofosbuvir
US20180030080A1 (en) * 2016-07-28 2018-02-01 Alexandre Vasilievich Ivachtchenko Phosphoramidate nucleoside prodrug for treating viral diseases and cancer, processes for their preparation and their use
CN109843900A (zh) * 2016-08-19 2019-06-04 桑多斯股份公司 治疗丙型肝炎的索非布韦衍生物
KR102456417B1 (ko) 2016-09-07 2022-10-19 아테아 파마슈티컬즈, 인크. Rna 바이러스 치료를 위한 2'-치환된-n6-치환된 퓨린 뉴클레오티드
WO2018078536A1 (en) 2016-10-26 2018-05-03 Lupin Limited Stable solid dispersion of sofosbuvir and process for preparation thereof
MA47094A (fr) 2016-12-22 2021-05-26 Idenix Pharmaceuticals Llc Promédicaments d'ester aliphatique antiviral de ténofovir
WO2018134343A1 (en) 2017-01-19 2018-07-26 Sandoz Ag Synthesis of phosphoramidates
WO2018136792A1 (en) 2017-01-20 2018-07-26 The Regents Of The University Of California Inhibitors of the n-terminal domain of the androgen receptor
CN110248951B (zh) 2017-02-01 2022-10-28 阿堤亚制药公司 用于治疗丙型肝炎病毒的核苷酸半硫酸盐
RU2650610C1 (ru) * 2017-02-28 2018-04-16 Васильевич Иващенко Александр Противовирусная композиция и способ ее применения
RU2659388C1 (ru) * 2017-02-28 2018-07-02 Васильевич Иващенко Александр Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение
RU2644156C1 (ru) * 2017-02-28 2018-02-08 Александр Васильевич Иващенко Пролекарство ингибитора NS5B HCV полимеразы, способ его получения и применения
KR102460968B1 (ko) 2017-03-14 2022-11-01 길리애드 사이언시즈, 인코포레이티드 고양이 코로나바이러스 감염의 치료 방법
ES2938859T3 (es) 2017-05-01 2023-04-17 Gilead Sciences Inc Una forma cristalina de (S)-2-etilbutilo 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato
RU2656228C9 (ru) * 2017-06-13 2019-04-16 Олег Ростиславович Михайлов Слабозакристаллизованная β-модификация (S)-изопропил 2-((S)-(((2R,3R,4R,5R)-5-(2,4-диоксо-3,4-дигидропиримидин-(2Н)-ил)-4-фтор-3-гидрокси-4-метилтетрагидрофуран-2-ил)метокси)-(фенокси)фосфориламино)пропаноата, способ её получения и фармацевтическая композиция на её основе
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
TW201919648A (zh) 2017-07-11 2019-06-01 美商基利科學股份有限公司 用於治療病毒感染之含rna聚合酶抑制劑與環糊精的組合物
EP3661944A1 (en) 2017-08-03 2020-06-10 Sandoz AG Sofosbuvir hydrate
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
US11111264B2 (en) 2017-09-21 2021-09-07 Chimerix, Inc. Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide and uses thereof
KR20200056420A (ko) * 2017-09-21 2020-05-22 리보사이언스 엘엘씨 Hcv rna 복제의 억제제로서 4'-플루오로-2'-메틸 치환된 뉴클레오시드 유도체
WO2019136389A1 (en) * 2018-01-05 2019-07-11 Cerecor, Inc. Nucleotide prodrugs
KR20200140865A (ko) 2018-04-10 2020-12-16 아테아 파마슈티컬즈, 인크. 간경변증을 갖는 hcv 감염 환자의 치료
NL2021049B1 (en) 2018-06-04 2019-12-11 Academisch Ziekenhuis Leiden Use of 6'-fluoro-neplanocin a derivatives against chikungunya virus
WO2020006489A1 (en) 2018-06-29 2020-01-02 The Regents Of The University Of California New molecular tweezers against neurological disorders and viral infections
SG11202100429TA (en) 2018-07-27 2021-02-25 California Inst Of Techn Cdk inhibitors and uses thereof
IL280639B (en) 2018-09-17 2022-07-01 Yungjin Pharmaceutical Co Ltd History of thiazoles and their pharmaceutically acceptable salts
KR20220023330A (ko) 2019-03-25 2022-03-02 캘리포니아 인스티튜트 오브 테크놀로지 Prmt5 억제제 및 이의 용도
WO2020236940A1 (en) 2019-05-20 2020-11-26 California Institute Of Technology Kras g12c inhibitors and uses thereof
TW202313067A (zh) 2020-01-27 2023-04-01 美商基利科學股份有限公司 治療sars cov-2感染之方法
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
JP2023516087A (ja) 2020-03-12 2023-04-17 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノヌクレオシドを調製する方法
TW202143949A (zh) 2020-03-22 2021-12-01 盈擘醫藥股份有限公司 用於預防或暴露後治療感染或呼吸疾病的抗病毒組成物
WO2021202669A2 (en) 2020-04-01 2021-10-07 Reyoung Corporation Nucleoside and nucleotide conjugate compounds and uses thereof
CN115362004A (zh) 2020-04-06 2022-11-18 吉利德科学公司 1’-氰基取代的碳核苷类似物的吸入制剂
CN111467363A (zh) * 2020-04-07 2020-07-31 中国科学院深圳先进技术研究院 索非布韦在制备预防和治疗冠状病毒的药物中的应用
JP2023528810A (ja) 2020-05-29 2023-07-06 ギリアード サイエンシーズ， インコーポレイテッド レムデシビル治療方法
KR20230028486A (ko) 2020-06-24 2023-02-28 길리애드 사이언시즈, 인코포레이티드 1'-시아노 뉴클레오시드 유사체 및 이의 용도
WO2021263072A1 (en) 2020-06-25 2021-12-30 Dana-Farber Cancer Institute, Inc. Methods of treating disease
KR20220005991A (ko) 2020-07-07 2022-01-14 (주)아이랩 신규한 tnf 활성 억제제 화합물 및 이의 약학적으로 허용가능한 염
WO2022035806A1 (en) 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. Fused tricyclic pyrimidine-thieno-pyridine small molecule inhibitors of ubiquitin-specific protease 28
EP4192811A1 (en) 2020-08-10 2023-06-14 Dana-Farber Cancer Institute, Inc. Substituted 3-amino-4-methylbenzenesulfonamides as small molecule inhibitors of ubiquitin-specific protease 28
CA3191164A1 (en) 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
TW202228722A (zh) 2020-08-27 2022-08-01 美商基利科學股份有限公司 用於治療病毒感染之化合物及方法
EP4225282A1 (en) * 2020-10-09 2023-08-16 ATEA Pharmaceuticals, Inc. Niran interfering drugs for sars-cov-2 mutant therapy
US20230399304A1 (en) 2020-10-23 2023-12-14 Dana-Farber Cancer Institute, Inc. Covalent inhibitors of creatine kinase (ck) and uses thereof for treating and preventing cancer
US20240058344A1 (en) 2020-12-18 2024-02-22 Cornell University Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
US11571481B2 (en) 2020-12-21 2023-02-07 Cornell University Peptide-linked drug delivery system
WO2022150574A1 (en) 2021-01-08 2022-07-14 Cornell University Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
CA3218884A1 (en) 2021-05-11 2022-11-17 David Nutt Therapeutic aminoindane compounds and compositions
CA3220228A1 (en) 2021-05-25 2022-12-01 Celia MORGAN Ketamine in the treatment of behavioural addictions
US11541071B1 (en) 2021-12-16 2023-01-03 Ascletis BioScience Co., Ltd Nucleoside derivatives and methods of use thereof
WO2023139163A1 (en) 2022-01-19 2023-07-27 Awakn Ls Europe Holdings Limited 1,3-benzodioxole esters and their therapeutic use
WO2023156565A1 (en) 2022-02-16 2023-08-24 Awakn Ls Europe Holdings Limited Bridged ring compounds and their therapeutic use as cns agents
WO2023167944A1 (en) 2022-03-02 2023-09-07 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
WO2023250157A1 (en) 2022-06-24 2023-12-28 Cornell University Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
WO2024013209A1 (en) 2022-07-13 2024-01-18 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof

Family Cites Families (303)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2007275A (en) 1933-01-09 1935-07-09 Elizabeth Q Kendall Ingot stripper
US2759300A (en) 1954-08-11 1956-08-21 Pest Control Ltd Method and means for introducing a predetermined amount of a poisonous material beneath the surface of the soil
US3798209A (en) 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
USRE29835E (en) 1971-06-01 1978-11-14 Icn Pharmaceuticals 1,2,4-Triazole nucleosides
US3852267A (en) 1972-08-04 1974-12-03 Icn Pharmaceuticals Phosphoramidates of 3{40 ,5{40 -cyclic purine nucleotides
JPS5116273A (ja) 1974-07-31 1976-02-09 Hitachi Ltd Datsushosochiniokeru nh3 chunyuryono seigyoho
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
NL8403224A (nl) 1984-10-24 1986-05-16 Oce Andeno Bv Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
GB8719367D0 (en) 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
JPH03501253A (ja) 1987-09-22 1991-03-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア エイズ（ａｉｄｓ）治療を目的とするリポソームによるヌクレオシド類似物質
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US6132763A (en) 1988-10-20 2000-10-17 Polymasc Pharmaceuticals Plc Liposomes
US5705363A (en) 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5026687A (en) 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
AU660925B2 (en) 1990-04-06 1995-07-13 Genelabs Technologies, Inc. Hepatitis C virus epitopes
AU7872491A (en) 1990-05-07 1991-11-27 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
WO1991018914A1 (en) 1990-05-29 1991-12-12 Vical, Inc. Synthesis of glycerol di- and triphosphate derivatives
DK0533833T3 (da) 1990-06-13 1996-04-22 Arnold Glazier Phosphorprolægemidler
US6060080A (en) 1990-07-16 2000-05-09 Daiichi Pharmaceutical Co., Ltd. Liposomal products
JP2599492B2 (ja) 1990-08-21 1997-04-09 第一製薬株式会社 リポソーム製剤の製造法
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5256641A (en) 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5157027A (en) 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
CA2112803A1 (en) 1991-07-12 1993-01-21 Karl Y. Hostetler Antiviral liponucleosides: treatment of hepatitis b
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
TW224053B (pl) 1991-09-13 1994-05-21 Paul B Chretien
US5676942A (en) 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
US5405598A (en) 1992-02-24 1995-04-11 Schinazi; Raymond F. Sensitizing agents for use in boron neutron capture therapy
JP3102945B2 (ja) 1992-02-27 2000-10-23 財団法人野田産業科学研究所 肝炎治療剤
US5610054A (en) 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
JP3291071B2 (ja) 1992-06-22 2002-06-10 イーライ・リリー・アンド・カンパニー アルファ−アノマーに富む１−ハロ−２−デオキシ−２，２−ジフルオロ−ｄ−リボフラノシル誘導体の製造方法
US5426183A (en) 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5256798A (en) 1992-06-22 1993-10-26 Eli Lilly And Company Process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates
US5301508A (en) 1992-08-14 1994-04-12 Rubbermaid Incorporated Thermoelectric portable container
CA2105112C (en) 1992-09-01 2005-08-02 Thomas C. Britton A process for anomerizing nucleosides
GB9226729D0 (en) 1992-12-22 1993-02-17 Wellcome Found Therapeutic combination
EP0686043B1 (en) 1993-02-24 1999-06-23 WANG, Jui, H. Compositions and methods of application of reactive antiviral polymers
US6180134B1 (en) 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
WO1994026273A1 (en) 1993-05-12 1994-11-24 Hostetler Karl Y Acyclovir derivatives for topical use
AU688344B2 (en) 1993-07-19 1998-03-12 Mitsubishi-Tokyo Pharmaceuticals, Inc. Hepatitis C virus proliferation inhibitor
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
US7375198B2 (en) 1993-10-26 2008-05-20 Affymetrix, Inc. Modified nucleic acid probes
WO1995013090A1 (en) 1993-11-10 1995-05-18 Enzon, Inc. Improved interferon polymer conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
AU6550394A (en) 1994-03-11 1995-09-25 Isis Pharmaceuticals, Inc. Novel pyrimidine nucleosides
DE4447588C2 (de) 1994-05-03 1997-11-20 Omer Osama Dr Dr Med Pflanzliches Arzneimittel zur Behandlung von chronischen und allergischen Rhino-Sino-Bronchitiden
JPH10501809A (ja) 1994-06-22 1998-02-17 ネクスター ファーマスーティカルズ，インコーポレイテッド 分子内求核置換による公知および新規２′−ヌクレオシドの新規製造方法
DE4432623A1 (de) 1994-09-14 1996-03-21 Huels Chemische Werke Ag Verfahren zur Bleichung von wäßrigen Tensidlösungen
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5696277A (en) 1994-11-15 1997-12-09 Karl Y. Hostetler Antiviral prodrugs
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
EP0806956B1 (de) 1995-02-01 2002-08-28 RESprotect GmbH Verwendung von 5' substituierten nukleosiden zur hemmung von resistenzbildung bei der zytostatikabehandlung
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
DE19514523A1 (de) 1995-04-12 1996-10-17 Schering Ag Neue Cytosin- und Cytidinderivate
WO1997012033A1 (en) 1995-09-27 1997-04-03 Emory University Recombinant hepatitis c virus rna replicase
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5767097A (en) 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
GB9602028D0 (en) 1996-02-01 1996-04-03 Amersham Int Plc Nucleoside analogues
US5980884A (en) 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
EP0914421A2 (en) 1996-02-29 1999-05-12 Immusol, Inc. Hepatitis c virus ribozymes
US5830905A (en) 1996-03-29 1998-11-03 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5990276A (en) 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
GB9609932D0 (en) 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
US5891874A (en) 1996-06-05 1999-04-06 Eli Lilly And Company Anti-viral compound
US5837257A (en) 1996-07-09 1998-11-17 Sage R&D Use of plant extracts for treatment of HIV, HCV and HBV infections
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
NZ334915A (en) 1996-10-16 2000-11-24 Icn Pharmaceuticals Monocyclic L-nucleosides, analogs thereof and their use in the modulation of Th1 and Th2 activities
KR100412480B1 (ko) 1996-10-16 2003-12-31 아이씨엔 파마슈티컬스, 인코포레이티드 푸린 ｌ-누클레오시드, 이의 유사체 및 이들의 용도
US6509320B1 (en) 1996-10-16 2003-01-21 Icn Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses thereof
US6455690B1 (en) 1996-10-16 2002-09-24 Robert Tam L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine
ZA979327B (en) 1996-10-18 1998-05-11 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease.
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
IL119833A (en) 1996-12-15 2001-01-11 Lavie David Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
DE69814878T2 (de) 1997-06-30 2004-05-19 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexane als nmda-rezeptor-antagonisten
DE69827956T2 (de) 1997-08-11 2005-04-14 Boehringer Ingelheim (Canada) Ltd., Laval Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
ATE206618T1 (de) 1997-09-21 2001-10-15 Schering Corp Kombinationstherapie zur entfernung von nachweisbarer hcv-rns in patienten mit chronischer hepatitis c-infektion
US6703374B1 (en) 1997-10-30 2004-03-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleosides for imaging and treatment applications
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
IL137164A0 (en) 1998-01-23 2001-07-24 Newbiotics Inc Enzyme catalyzed therapeutic agents
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
EA008609B1 (ru) 1998-02-25 2007-06-29 Эмори Юниверсити 2'-фторнуклеозиды
US6787305B1 (en) 1998-03-13 2004-09-07 Invitrogen Corporation Compositions and methods for enhanced synthesis of nucleic acid molecules
WO1999049873A1 (en) 1998-03-27 1999-10-07 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
ES2281170T3 (es) * 1998-03-31 2007-09-16 Vertex Pharmaceuticals Incorporated Inhibidores de serina proteasas, particularmente proteasa ns3 del virus de la hepatitis c.
HU230432B1 (hu) 1998-05-15 2016-06-28 Merck Sharp & Dohme Corp Ribavirint és alfa-interferont tartalmazó kombinált terápia vírusellenes kezelésben nem részesült, krónikus hepatitis C fertőzött paciensek kezelésében
SI1087778T1 (sl) 1998-06-08 2006-02-28 Hoffmann La Roche Uporaba peg-ifn-alfa in ribavirina za zdravljenje kronicnega hepatitisa c
US6492423B1 (en) 1998-07-27 2002-12-10 Istituto Di Ricerche Di Biologia Molecolare Pangeletti Spa Diketoacid-derivatives as inhibitors of polymerases
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AU5475799A (en) 1998-08-10 2000-03-06 Centre National De La Recherche Scientifique Beta-l-2'-deoxy-nucleosides for the treatment of hepatitis
AU2157000A (en) 1998-12-18 2000-07-12 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
WO2001007454A1 (en) 1999-07-22 2001-02-01 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
SK1512002A3 (en) 1999-07-30 2002-11-06 Abbott Gmbh & Co Kg 2-pyrazolin-5-ones
WO2001032153A2 (en) 1999-11-04 2001-05-10 Shire Biochem Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
EP1232166A2 (en) 1999-11-12 2002-08-21 Pharmasset Limited Synthesis of 2'-deoxy-l-nucleosides
US6495677B1 (en) 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
EP1296690A2 (en) 2000-02-18 2003-04-02 Shire Biochem Inc. METHOD FOR THE TREATMENT OR PREVENTION OF i FLAVIVIRUS /i INFECTIONS USING NUCLEOSIDE ANALOGUES
WO2001079246A2 (en) 2000-04-13 2001-10-25 Pharmasset, Ltd. 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections
US6924270B2 (en) 2000-04-20 2005-08-02 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
AU2001272923A1 (en) 2000-05-26 2001-12-11 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
CA2410488C (en) 2000-05-26 2009-10-27 Idenix (Cayman) Limited Methods of treating hepatitis delta virus infection with .beta.-l-2' deoxy-nucleosides
FR2810322B1 (fr) 2000-06-14 2006-11-10 Pasteur Institut PRODUCTION COMBINATOIRE D'ANALOGUES DE NUCLEOTIDES ET NUCLEOTIDES (XiTP)
MY141594A (en) 2000-06-15 2010-05-14 Novirio Pharmaceuticals Ltd 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
US6815542B2 (en) 2000-06-16 2004-11-09 Ribapharm, Inc. Nucleoside compounds and uses thereof
UA72612C2 (en) 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
JP4651264B2 (ja) 2000-07-21 2011-03-16 ギリアード サイエンシーズ， インコーポレイテッド ホスホネートヌクレオチドアナログのプロドラッグならびにこれを選択および作製するための方法。
HUP0303358A3 (en) 2000-07-21 2005-10-28 Schering Corp Novel peptides as ns3-serine protease inhibitors of hepatitis c virus and pharmaceutical compositions containing them
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
WO2002008251A2 (en) 2000-07-21 2002-01-31 Corvas International, Inc. Peptides as ns3-serine protease inhibitors of hepatitis c virus
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
US6897201B2 (en) 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
AR039558A1 (es) 2000-08-21 2005-02-23 Inspire Pharmaceuticals Inc Composiciones y metodo para el tratamiento de glaucoma o hipertension ocular
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
CN101862345B (zh) * 2000-10-18 2014-06-04 吉利德制药有限责任公司 用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物
AU2002213343A1 (en) 2000-10-18 2002-04-29 Schering Corporation Ribavirin-pegylated interferon alfa HCV combination therapy
US6555677B2 (en) 2000-10-31 2003-04-29 Merck & Co., Inc. Phase transfer catalyzed glycosidation of an indolocarbazole
WO2002060926A2 (en) 2000-11-20 2002-08-08 Bristol-Myers Squibb Company Hepatitis c tripeptide inhibitors
IL155842A0 (en) 2000-12-12 2003-12-23 Schering Corp Diaryl peptides as ns3-serine protease inhibitors of hepatitis c virus
AU2002230763A1 (en) 2000-12-13 2008-01-03 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
US6727366B2 (en) 2000-12-13 2004-04-27 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors
BR0116221A (pt) 2000-12-15 2005-09-13 Pharmasset Ltd Agentes antivirais para tratamento de infecções por flaviviridae
CA2434386C (en) 2001-01-22 2006-12-05 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
GB0112617D0 (en) 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
WO2003000713A1 (en) 2001-06-21 2003-01-03 Glaxo Group Limited Nucleoside compounds in hcv
MXPA04000293A (es) 2001-07-11 2004-05-04 Vertex Pharma Inhibidores de serina proteasa biciclica de puente.
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US6962991B2 (en) 2001-09-12 2005-11-08 Epoch Biosciences, Inc. Process for the synthesis of pyrazolopyrimidines
US7227019B2 (en) 2001-09-13 2007-06-05 Bristol-Myers Squibb Company Process for the preparation of rebeccamycin and analogs thereof
WO2003024461A1 (en) 2001-09-20 2003-03-27 Schering Corporation Hcv combination therapy
EP1435974A4 (en) 2001-09-28 2006-09-06 Idenix Cayman Ltd METHOD AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS WITH 4'-MODIFIED NUCLEOSIDES
ES2289161T3 (es) 2001-11-02 2008-02-01 Glaxo Group Limited Derivados de 4-(heteroaril de 6 miembros)-acil pirrolidina como inhibidores de hcv.
GB0129945D0 (en) 2001-12-13 2002-02-06 Mrc Technology Ltd Chemical compounds
WO2003063771A2 (en) 2001-12-14 2003-08-07 Pharmasset Ltd. N4-acylcytosine nucleosides for treatment of viral iinfections
WO2003051899A1 (en) 2001-12-17 2003-06-26 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
EP1458735A2 (en) 2001-12-21 2004-09-22 Micrologix Biotech, Inc. Anti-viral 7-deaza l-nucleosides
WO2003062256A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7323453B2 (en) 2002-02-13 2008-01-29 Merck & Co., Inc. Methods of inhibiting orthopoxvirus replication with nucleoside compounds
EP1485395A4 (en) 2002-02-28 2011-04-13 Biota Scient Management NUCLEOTIDE MIMETICS AND PRODRUGS THEREOF
AU2003213628A1 (en) 2002-02-28 2003-09-16 Biota, Inc. Nucleoside 5'-monophosphate mimics and their prodrugs
AU2003241621A1 (en) 2002-05-24 2003-12-12 Isis Pharmaceuticals, Inc. Oligonucleotides having modified nucleoside units
CA2487211C (en) 2002-06-04 2010-09-14 Neogenesis Pharmaceuticals, Inc. Pyrazolo(1,5a) pyrimidine compounds as antiviral agents
US7906491B2 (en) 2002-06-07 2011-03-15 Univisitair Medisch Centrum Utrecht Compounds for modulating the activity of exchange proteins directly activated by cAMP (Epacs)
AU2003251524A1 (en) 2002-06-17 2003-12-31 Isis Pharmaceuticals, Inc. Carbocyclic nucleoside analogs as RNA-antivirals
AU2003248708A1 (en) 2002-06-17 2003-12-31 Isis Pharmaceuticals, Inc. Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
CA2488534A1 (en) 2002-06-21 2003-12-31 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US20060234962A1 (en) 2002-06-27 2006-10-19 Olsen David B Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US7662798B2 (en) 2002-06-28 2010-02-16 Idenix Pharmaceuticals, Inc. 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN103319554A (zh) 2002-06-28 2013-09-25 埃迪尼克斯医药公司 用于治疗黄病毒感染的修饰的2’和3’-核苷前药
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
RS114104A (en) 2002-06-28 2007-02-05 Idenix (Cayman) Limited, 2' and 3'-nucleoside prodrugs for treating flaviviridae infections
CN101172992A (zh) * 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的修饰的2′和3′－核苷前药
MXPA05000255A (es) 2002-07-01 2005-07-15 Pharmacia & Upjohn Co Llc Inhibidores de polimerasa de ns5b de hcv.
EP1532128A1 (en) 2002-07-01 2005-05-25 Pharmacia & Upjohn Company LLC Inhibitors of hcv ns5b polymerase
US6973905B2 (en) 2002-07-01 2005-12-13 Cinetic Automation Corporation Valve lash adjustment apparatus and method
AU2003269902A1 (en) 2002-07-16 2004-02-02 Isis Pharmaceuticals, Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2004009020A2 (en) 2002-07-24 2004-01-29 Merck & Co., Inc. Pyrrolopyrimidine thionucleoside analogs as antivirals
CA2493816A1 (en) 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
WO2004011478A2 (en) 2002-07-25 2004-02-05 Micrologix Biotech Inc. Anti-viral 7-deaza d-nucleosides and uses thereof
US7183302B2 (en) 2002-08-12 2007-02-27 Bristol-Myers Squibb Company Iminothiazolidinones as inhibitors of HCV replication
CN100536853C (zh) 2002-09-13 2009-09-09 艾登尼科斯（开曼）有限公司 β-L-2′-脱氧核苷用于治疗抗性HBV株以及联合治疗
CA2501547A1 (en) 2002-10-15 2004-04-29 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
US20040229840A1 (en) 2002-10-29 2004-11-18 Balkrishen Bhat Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
UA79834C2 (en) 2002-11-01 2007-07-25 Viropharma Inc Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
JP2006519753A (ja) 2002-11-15 2006-08-31 イデニクス（ケイマン）リミテツド ２’−分枝ヌクレオシドおよびフラビウイルス科ウイルス突然変異
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
ES2470771T3 (es) 2002-12-12 2014-06-24 Idenix Pharmaceuticals, Inc Procedimiento para la producción de nucle�sidos ramificados en 2'
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2004080466A1 (en) 2003-03-07 2004-09-23 Ribapharm Inc. Cytidine analogs and methods of use
WO2004084453A2 (en) 2003-03-20 2004-09-30 Microbiologica Quimica E Farmaceutica Ltd. METHODS OF MANUFACTURE OF 2'-DEOXY-β-L-NUCLEOSIDES
JP4733023B2 (ja) 2003-04-16 2011-07-27 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルスの大環状イソキノリンペプチド阻害剤
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US20050261237A1 (en) 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
PT1628685E (pt) 2003-04-25 2011-03-16 Gilead Sciences Inc Análogos de fosfonatos antivirais
BRPI0409680A (pt) 2003-04-25 2006-04-18 Gilead Sciences Inc análogos de fosfonato anti-cáncer
KR20060022647A (ko) 2003-04-25 2006-03-10 길리애드 사이언시즈, 인코포레이티드 키나아제 억제 포스포네이트 유사체
US20040259934A1 (en) 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
WO2004096210A1 (en) 2003-05-01 2004-11-11 Glaxo Group Limited Acylated indoline and tetrahydroquinoline derivatives as hcv inhibitors
EP1656093A2 (en) 2003-05-14 2006-05-17 Idenix (Cayman) Limited Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
SI2604620T1 (sl) 2003-05-30 2016-10-28 Gilead Pharmasset LLC c/o Gilead Sciences, Inc. Modificirani fluorirani nukleozidni analogi
EP1644479A4 (en) 2003-06-16 2008-04-23 Mark W Grinstaff MACROMOLECULES AND FUNCTIONAL SYNTHETIC MOLECULES FOR GENES ADMINISTRATION
RU2243972C1 (ru) 2003-06-26 2005-01-10 Государственный научный центр вирусологии и биотехнологии "Вектор" Фосфорамидаты нуклеозидных аналогов - ингибиторы репродукции вируса иммунодефицита человека
CA2531412A1 (en) 2003-06-30 2005-01-13 Idenix (Cayman) Limited Synthesis of .beta.-l-2'-deoxy nucleosides
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
RU2006105640A (ru) 2003-07-25 2007-09-10 Айденикс (Кайман) Лимитед (Ky) Аналоги пуриновых нуклеозидов для лечения flaviviridae, включая гепатит с
EP1660511B1 (en) 2003-08-27 2010-11-03 Biota Scientific Management Pty. Ltd. Novel tricyclic nucleosides or nucleotides as therapeutic agents
EP1664091A1 (en) 2003-09-18 2006-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US20050148534A1 (en) 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
US7348389B2 (en) 2003-09-22 2008-03-25 E. I. Du Pont De Nemours And Company Method for achieving recoat adhesion over a fluorinated topcoat
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
WO2005037214A2 (en) 2003-10-14 2005-04-28 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
US7157434B2 (en) * 2003-10-27 2007-01-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
US7026339B2 (en) 2003-11-07 2006-04-11 Fan Yang Inhibitors of HCV NS5B polymerase
TW200528459A (en) 2004-01-06 2005-09-01 Achillion Pharmaceuticals Inc Azabenzofuran substituted thioureas; inhibitors of viral replication
CN1913778A (zh) 2004-01-28 2007-02-14 默克公司 趋化因子受体活性的氨基环戊基吡啶并吡嗪酮调节剂
WO2005082144A1 (en) 2004-02-25 2005-09-09 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer Methylation inhibitor compounds
WO2005087788A2 (en) 2004-03-04 2005-09-22 The Regents Of The University Of California Methods for preparation of nucleoside phosphonate esters
AU2005228894B9 (en) 2004-03-30 2011-10-13 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
GB0408995D0 (en) 2004-04-22 2004-05-26 Glaxo Group Ltd Compounds
US7534767B2 (en) 2004-06-15 2009-05-19 Merck & Co., Inc. C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase
WO2006000922A2 (en) 2004-06-23 2006-01-05 Idenix (Cayman) Limited 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
AU2005267421B2 (en) * 2004-06-24 2010-06-03 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
US7217523B2 (en) 2004-07-02 2007-05-15 Regents Of The University Of Minnesota Nucleoside phosphoramidates and nucleoside phosphoramidases
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
EP1773856B1 (en) 2004-07-21 2012-02-01 Pharmasset, Inc. Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
ME01945B (me) 2004-07-27 2011-12-31 Gilead Sciences Inc Nukleozid-fosfonatni konjugati kao sredstva protiv hiv-a
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
CN101044151B (zh) 2004-08-23 2011-01-19 弗·哈夫曼-拉罗切有限公司 抗病毒的4＇-叠氮基-核苷
RU2007110531A (ru) 2004-08-23 2008-09-27 Ф.Хоффманн-Ля Рош Аг (Ch) Гетероциклические противовирусные соединения
WO2006029081A2 (en) 2004-09-02 2006-03-16 Neopharm, Inc. Nucleoside-lipid conjugates, their method of preparation and uses thereof
PT3109244T (pt) 2004-09-14 2019-06-04 Gilead Pharmasset Llc ¿preparação de ribofuranosil pirimidinas e purinas 2¿-fluoro-2¿-alquil substituídas ou outras opcionalmente substituídas e os seus derivados
AU2005289517A1 (en) 2004-09-24 2006-04-06 Centre National De La Recherche Scientifique Methods and compositions for treating flaviviruses, pestiviruses and hepacivirus
CA2577745C (en) 2004-09-30 2012-11-27 Tibotec Pharmaceuticals Ltd. Hcv inhibiting bi-cyclic pyrimidines
US20080280842A1 (en) * 2004-10-21 2008-11-13 Merck & Co., Inc. Fluorinated Pyrrolo[2,3-D]Pyrimidine Nucleosides for the Treatment of Rna-Dependent Rna Viral Infection
EP1814561A4 (en) 2004-10-29 2012-12-19 Biocryst Pharm Inc THEROPUTICAL FUROPYRIMIDINES AND THIENOPYRIMIDINES
US20060116557A1 (en) 2004-11-30 2006-06-01 Alere Medical Incorporated Methods and systems for evaluating patient data
EP1827460A4 (en) 2004-12-09 2012-03-14 Univ Minnesota NUCLEOSIDE WITH ANTIVIRAL AND ANTI-CANCER EFFECT
WO2006065590A2 (en) 2004-12-16 2006-06-22 Xtl Biopharmaceuticals Inc. Pyridine and pyrimidine antiviral compositions
WO2006063717A2 (en) 2004-12-16 2006-06-22 Febit Biotech Gmbh Polymerase-independent analysis of the sequence of polynucleotides
EP1674104A1 (en) 2004-12-24 2006-06-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Uridine derivatives as antiviral drugs against a flaviviridae, especially HCV
WO2006093801A1 (en) 2005-02-25 2006-09-08 Abbott Laboratories Thiadiazine derivatives useful as anti-infective agents
AR058419A1 (es) 2005-02-28 2008-02-06 Gilead Sciences Inc Compuestos de nucleosidos triciclicos para tratar infecciones virales
US20060199738A1 (en) 2005-03-04 2006-09-07 Sumitomo Chemical Company, Limited Herbicidal composition
WO2006100310A1 (en) 2005-03-25 2006-09-28 Tibotec Pharmaceuticals Ltd Heterobicylic inhibitors of hcv
TW200720285A (en) * 2005-04-25 2007-06-01 Genelabs Tech Inc Nucleoside compounds for treating viral infections
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
AR056347A1 (es) 2005-05-12 2007-10-03 Tibotec Pharm Ltd Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
TW200716631A (en) 2005-05-12 2007-05-01 Tibotec Pharm Ltd Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof
WO2007027248A2 (en) 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
US20060293752A1 (en) 2005-06-27 2006-12-28 Missoum Moumene Intervertebral disc prosthesis and associated methods
EP1924594A2 (en) 2005-07-25 2008-05-28 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
EA014293B1 (ru) 2005-07-29 2010-10-29 Тиботек Фармасьютикалз Лтд. Макроциклические ингибиторы вируса гепатита с
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
AR055361A1 (es) 2005-07-29 2007-08-22 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
AR055105A1 (es) 2005-07-29 2007-08-08 Tibotec Pharm Ltd Inhibidores macrociclicos del virus de la hepatitis c
PL1919904T3 (pl) 2005-07-29 2014-06-30 Janssen R&D Ireland Makrocykliczne inhibitory wirusa zapalenia wątroby typu C
WO2007020193A2 (en) * 2005-08-15 2007-02-22 F. Hoffmann-La Roche Ag Antiviral phosphoramidates of 4 ' -substituted pronucleotides
GB0519478D0 (en) 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519488D0 (en) 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
WO2007065829A1 (en) 2005-12-09 2007-06-14 F. Hoffmann-La Roche Ag Antiviral nucleosides
WO2007070556A2 (en) 2005-12-12 2007-06-21 Genelabs Technologies, Inc. N-(6-membered aromatic ring)-amido anti-viral compounds
RU2441869C2 (ru) 2005-12-21 2012-02-10 Эбботт Лэборетриз Противовирусные соединения
GB0602046D0 (en) 2006-02-01 2006-03-15 Smithkline Beecham Corp Compounds
WO2007092000A1 (en) 2006-02-06 2007-08-16 Bristol-Myers Squibb Company Inhibitors of hcv replication
JP2009526850A (ja) 2006-02-14 2009-07-23 メルク エンド カムパニー インコーポレーテッド Ｒｎａ依存性ｒｎａウイルス感染を治療するためのヌクレオシドアリールホスホルアミデート
BRPI0707945A2 (pt) 2006-02-17 2011-05-17 Pfizer Ltd derivados de 3-deazapurina como modulares de tlr7
US8895531B2 (en) 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
EP2029606B1 (en) 2006-05-25 2010-05-26 Brystol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
AP2985A (en) 2006-07-07 2014-09-30 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
EP1881001A1 (en) 2006-07-20 2008-01-23 Tibotec Pharmaceuticals Ltd. HCV NS-3 serine protease inhibitors
US8912321B2 (en) 2006-10-10 2014-12-16 Gilead Pharmasset Llc Preparation of nucleosides ribofuranosyl pyrimidines
PL216525B1 (pl) 2006-10-17 2014-04-30 Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk 5'-O-[(N-acylo)amidoditiofosforano] nukleozydy oraz sposób wytwarzania 5'-O-[(N-acylo)amidofosforano]-,5'-O-[(N-acylo)amidotiofosforano]-, 5'-O-[(N-acylo)amidoditiofosforano]nukleozydów
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US8148349B2 (en) 2006-12-20 2012-04-03 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
AU2007342367B2 (en) 2007-01-05 2012-12-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
WO2008104408A2 (en) 2007-02-27 2008-09-04 K. U. Leuven Research & Development Phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
GB0709791D0 (en) 2007-05-22 2007-06-27 Angeletti P Ist Richerche Bio Antiviral agents
CN101108870A (zh) 2007-08-03 2008-01-23 冷一欣 核苷磷酸酯类化合物及制备方法和应用
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain vehicles, installations and methods
JP5238939B2 (ja) 2007-11-07 2013-07-17 三菱化学株式会社 長繊維強化複合樹脂組成物および成形品
WO2009086192A1 (en) 2007-12-21 2009-07-09 Alios Biopharma, Inc. Biodegradable phosphate protected nucleotide derivatives and their use as cancer, anti viral and anti parasitic agents
US8227431B2 (en) 2008-03-17 2012-07-24 Hetero Drugs Limited Nucleoside derivatives
US20110130440A1 (en) 2008-03-26 2011-06-02 Alnylam Pharmaceuticals, Inc. Non-natural ribonucleotides, and methods of use thereof
WO2009129120A2 (en) 2008-04-15 2009-10-22 Rfs Pharma, Llc Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010009121A2 (en) 2008-07-15 2010-01-21 University Of Florida Research Foundation, Inc. Colon stem cells associated with colitis and colorectal cancer and methods of use
US20110229438A1 (en) 2008-10-09 2011-09-22 Anadys Pharmaceuticals, Inc. Method of inhibiting hepatitus c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
WO2010075517A2 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside analogs
MX2011006891A (es) 2008-12-23 2011-10-06 Pharmasset Inc Fosforamidatos de nucleosidos.
EA019295B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Соединения пуриновых нуклеозидов и способ их получения
RU2011127079A (ru) 2009-01-07 2013-02-20 Сайнексис, Инк. Комбинация производного циклоспорина и нуклеозидов для лечения инфекции вирусом гепатита с
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
HUE034239T2 (en) 2010-03-31 2018-02-28 Gilead Pharmasset Llc Method for Crystallization of (S) -isopropyl 2 - (((S) (perfluorophenoxy) (phenoxy) phosphoryl) amino) propanoate \ t
US20120107278A1 (en) 2010-10-29 2012-05-03 Pharmasset, Inc. Abbreviated hcv therapy for hcv infected patients with il28b c/c genotype
US20130109647A1 (en) 2011-10-31 2013-05-02 Gilead Pharmasset Llc Methods and compositions for treating hepatitis c virus
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus

Also Published As

Publication number Publication date
KR20100016041A (ko) 2010-02-12
US20110257122A1 (en) 2011-10-20
NL300704I2 (pl) 2015-12-29
ES2492470T3 (es) 2014-09-09
US20100016251A1 (en) 2010-01-21
CA2682230C (en) 2014-04-22
PL2801580T3 (pl) 2024-02-12
JP2018197245A (ja) 2018-12-13
US8957046B2 (en) 2015-02-17
CN109456373A (zh) 2019-03-12
PL2826784T3 (pl) 2019-11-29
ES2963716T3 (es) 2024-04-01
HRP20140667T1 (hr) 2014-10-10
JP2010532747A (ja) 2010-10-14
NZ579880A (en) 2012-05-25
SG2014011704A (en) 2014-05-29
CN116731098A (zh) 2023-09-12
EP4282482A2 (en) 2023-11-29
US9585906B2 (en) 2017-03-07
US20140045783A1 (en) 2014-02-13
RU2012152811A (ru) 2014-06-20
LTPA2014040I1 (lt) 2021-08-10
SI2801580T1 (sl) 2024-01-31
SI2203462T1 (sl) 2014-09-30
CY1115488T1 (el) 2017-01-04
BRPI0823519A2 (pt) 2015-10-27
KR101432860B1 (ko) 2014-08-26
EP2203462A2 (en) 2010-07-07
KR20150008929A (ko) 2015-01-23
JP2012121903A (ja) 2012-06-28
CN109970830A (zh) 2019-07-05
JP5318085B2 (ja) 2013-10-16
SI2826784T1 (sl) 2019-10-30
US8334270B2 (en) 2012-12-18
CN109776637B (zh) 2023-04-18
LTC2203462I2 (lt) 2021-08-25
CN101918425B (zh) 2023-05-02
KR101527701B1 (ko) 2015-06-09
TW200904453A (en) 2009-02-01
US20140187511A1 (en) 2014-07-03
RU2018103329A (ru) 2019-08-05
US20210196741A1 (en) 2021-07-01
NZ599206A (en) 2013-08-30
AU2008232827B2 (en) 2012-08-16
HK1206033A1 (en) 2015-12-31
CO6260023A2 (es) 2011-03-22
IL201239A (en) 2013-03-24
HUS1400059I1 (hu) 2017-07-28
US11642361B2 (en) 2023-05-09
US10183037B2 (en) 2019-01-22
NO2014029I2 (no) 2014-11-18
JP2016023187A (ja) 2016-02-08
EP2203462B1 (en) 2014-05-21
CN101918425A (zh) 2010-12-15
IL217228A0 (en) 2012-01-31
EP2824109A1 (en) 2015-01-14
LU92600I2 (fr) 2015-11-24
MX2009010401A (es) 2009-11-10
DK2203462T3 (da) 2014-08-11
KR20120034801A (ko) 2012-04-12
EP2801580B1 (en) 2023-09-13
RU2651892C3 (ru) 2020-01-21
CN116731099A (zh) 2023-09-12
JP2014196305A (ja) 2014-10-16
PT2203462E (pt) 2014-08-29
US20180000855A1 (en) 2018-01-04
ZA201200310B (en) 2013-05-29
US9085573B2 (en) 2015-07-21
EP2826784B1 (en) 2019-06-26
FR14C0082I2 (fr) 2015-11-13
JP5774749B2 (ja) 2015-09-09
EP2826784A1 (en) 2015-01-21
JP2015024998A (ja) 2015-02-05
US20150231166A1 (en) 2015-08-20
IL201239A0 (en) 2010-05-31
CN109970818A (zh) 2019-07-05
US20140315852A1 (en) 2014-10-23
RU2478104C2 (ru) 2013-03-27
US8735372B2 (en) 2014-05-27
WO2008121634A3 (en) 2010-05-20
TWI357332B (en) 2012-02-01
EP2801580A1 (en) 2014-11-12
ZA200906647B (en) 2013-06-26
HK1206034A1 (en) 2015-12-31
KR101525293B1 (ko) 2015-06-03
ES2745462T3 (es) 2020-03-02
IL217228A (en) 2013-08-29
PH12014502771A1 (en) 2015-10-26
PT2826784T (pt) 2019-09-12
JP6377781B2 (ja) 2018-08-22
SG179445A1 (en) 2012-04-27
BRPI0809654A2 (pt) 2015-04-22
JP2017132754A (ja) 2017-08-03
US7964580B2 (en) 2011-06-21
JP2020100617A (ja) 2020-07-02
NO2014029I1 (no) 2014-12-01
US8906880B2 (en) 2014-12-09
US20130029929A1 (en) 2013-01-31
CY2014047I1 (el) 2017-07-12
AR066898A1 (es) 2009-09-23
CA2682230A1 (en) 2008-10-09
FR14C0082I1 (pl) 2014-12-26
AU2008232827A1 (en) 2008-10-09
RU2651892C2 (ru) 2018-04-24
PT2801580T (pt) 2023-12-06
DE202008018643U1 (de) 2017-03-16
US8580765B2 (en) 2013-11-12
CN104402955A (zh) 2015-03-11
NL300704I1 (pl) 2015-12-29
CL2008000902A1 (es) 2008-11-07
EP4282482A3 (en) 2024-01-17
IL222810A0 (en) 2012-12-31
AU2008232827C1 (en) 2015-04-09
CN109776637A (zh) 2019-05-21
RU2009139968A (ru) 2011-05-10
US20140288020A1 (en) 2014-09-25
CY2014047I2 (el) 2017-07-12
MY147409A (en) 2012-11-30
WO2008121634A2 (en) 2008-10-09
EP2792680A1 (en) 2014-10-22
EP2933260A1 (en) 2015-10-21
RU2018103329A3 (pl) 2021-05-24
JP5539419B2 (ja) 2014-07-02

Similar Documents

Publication Publication Date Title
HK1206034A1 (en) Nucleoside phosphoramidate prodrugs
IL213698A0 (en) Nucleoside phosphoramidates
HRP20140223T1 (en) Dolutegravir prodrugs
ZA201008829B (en) Nucleoside cyclicphosphates
HUE036318T2 (hu) Módosított foszfatázok
ZA201104638B (en) Nucleoside analogs
HK1127295A1 (en) Antiviral phosphinate compounds
ZA201004371B (en) Efficient aspirin prodrugs
IL200832A0 (en) Phosphorus recovery
ZA201003438B (en) Antiviral nucleoside compounds
EP2118052A4 (en) NEW PRODRUGS
HK1131550A1 (en) L-oddc prodrugs for cancer
AP2008004705A0 (en) Pnem prodrugs
EP2127540A4 (en) SKIN EMBELLISHMENT MEDIUM
AU2014215983B2 (en) Nucleoside phosphoramidate prodrugs
TH0801001634A (th) โปรดรักส์ (Prodrugs) นิวคลีโอไซด์ ฟอสโฟรามิเดต
AU2008906122A0 (en) AICA Riboside Prodrugs
AP2008004721A0 (en) Antiviral phosphinate compounds